A drug that boosts bone growth in children with achondroplasia — the most common form of dwarfism — may also reduce their chances of SIDS, sleep apnoea and needing surgery.
Children of all ages with achondroplasia are now included in the expanded Indication, the most common form of skeletal dysplasia leading to disproportionate short stature.